Advertisement
Insights on the decision process for selecting a treatment approach
New reports focus on neuroimaging biomarkers and features of atypical presentations
Perhaps, with caveats: sNfL elevation has low sensitivity and lags MRI activity by at least a month
Early experience with the agents confirms findings from clinical trials
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Findings challenge dogma that microglia are exclusively destructive regardless of location in brain
New review distills insights from studies over the past decade
Updated consensus approach helps clinicians efficiently improve diagnostic accuracy
The disease is not a barrier to pregnancy, but risks from disease-modifying therapies must be managed
In search of optimal imaging biomarkers, best methods for long-term follow-up
Risk of new MS activity is small in those older than 55 with stable disease who stop MS therapy
Advertisement
Advertisement